Navigation Links
Circadian Receives FDA IND Approval to Begin Clinical Trials With VGX-100 for the Treatment of Cancer Patients With Solid Tumors
Date:10/31/2011

gned to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Circadian are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Thus investment in companies specialising in drug development must be regarded as highly speculative. Circadian strongly recommends that professional investment advice be sought prior to such investments.

Forward-looking statements Certain statements in this ASX announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavor of building a business around such products and services. Circadian undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those discussed in this ASX announcement.


'/>"/>

SOURCE Circadian Technologies Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Circadian Files IND With FDA for VGX-100 for the Treatment of Cancer Patients With Solid Tumors
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Cyberonics Receives FDA Approval for Expansion of MRI Use With VNS Therapy® Systems
4. Mylan Receives Approval for Generic Version of MS Contin® Tablets
5. SAFC Verona HPAPI Manufacturing Facility Receives SafeBridge Certification
6. INNOPHARMA Receives FDA Approval of Generic Olanzapine Injection
7. Accuray Receives 510(k) Clearance for a Rotational Dose Control for the TomoTherapy System
8. Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial
9. Covance Receives Good Laboratory Practice Certification for Its Early Development Facility in Shanghai, China
10. Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets
11. Institute of Health Sciences Receives ABHES Institutional Accreditation for Long Distance Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... RMD ) today announced results for its quarter ended ... a 10 percent increase compared to the quarter ended December ... basis). Net income was $91.2 million, an increase of 5 ... earnings per share for the quarter were $0.64, an increase ...
(Date:1/22/2015)...  Profil Institute for Clinical Research, Inc., a clinical research ... a new textbook,  Translational Research Methods for Diabetes, Obesity ... global scientific publisher. The textbook is the ... in early phase clinical studies of new drugs for ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... Diagnostics Market by Allergen Source, Product & by End User ... The global allergy diagnostics market is valued ... at a CAGR of 12.67%, to reach $2,230.72 million by ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... 7, 2011  Inovio Pharmaceuticals, Inc. (NYSE Amex: ... cancers and infectious diseases, announced today that it has ... its common stock and warrants to purchase up to ... the partial exercise of the underwriter,s overallotment option to ...
... FRANCISCO, Calif., Dec. 6, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... a teleconference and webcast to reprise key carfilzomib data presentations ... (ASH) Annual Meeting in San Diego, California. The ... 2011.  Interested parties may access the teleconference ...
Cached Medicine Technology:Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 2Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 3Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 4
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and easy ... treat specific body parts and muscle groups. , IsoComforter, ... use patented cold therapy machine with the innovative IsoTube design ... injuries. IsoComforter has become the industry leader in cold ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the ... in an effort to further promote visibility and adoption of ... long made AMA journals available via its subscription services, EBSCO ... Network. , Long known as both a subscription ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a list ... policy . , Some types of vehicles cannot be covered ... released blog post to see if their vehicle qualifies for auto ... some of the cars that cannot be covered by a plan. ...
(Date:1/22/2015)... State Forestry Institute of Mecklenburg-Vorpommern in Germany ... from GEOSYSTEMS, a dedicated Hexagon Geospatial and Intergraph partner ... Geospatial’s ERDAS APOLLO for cataloging, managing, and ... clouds and documents. This effort will enable the State ...
Breaking Medicine News(10 mins):Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... today inaugurated a new 120-bed drug de-addiction centre with a ... of Asia’s biggest prisons having over 13,000 inmates. The ... built at a cost of Rs.17 million. ... started in any jail in the country for treatment, post-treatment ...
... of chromium as the shiny metal in the bumpers of ... a crucial role in human health//, reports Harvard Men’s Health ... deficiency leads to high cholesterol levels. In humans, the results ... early to recommend chromium supplements for cholesterol. But there may ...
... recent study suggest that - Telephone outreach can dramatically ... in an urban minority// population, constituting predominantly of black ... that black minority does not believe in getting regular ... conducted regularly via three day stool blood test, reduces ...
... 50% of the HIV infection rate among heterosexual men has ... seeking it.// , ,2,500 Ugandan males were ... nearly half were adults. Less than 400 adult males were ... that new HIV infections among circumcised heterosexual men in Uganda ...
... uncovered the possible causes for brain disorders such as ... November 1, 2006 in the prestigious journal Nature Neuroscience. ... regional blood flow changes in the brain. To function ... of oxygen and glucose, which is provided through an ...
... a customised personal digital assistant (PDA) to dramatically ... said Thursday. ,Instead of fumbling with ... speech impairments express their needs in such everyday ... attention from an archive of commonly-used phrases and ...
Cached Medicine News:Health News:Chromium May Help Diabetes, Cholesterol, and Heart Disease 2Health News:Telephone Outreach Boost CRC Screening In Urban Minority 2Health News:Potential Key to Brain Blood-Flow Disorders Explored by Scientists 2Health News:Potential Key to Brain Blood-Flow Disorders Explored by Scientists 3Health News:Potential Key to Brain Blood-Flow Disorders Explored by Scientists 4
Inquire...
Inquire...
Supercassette quick release holder for the 8000 Series sliding microtome to allow for the use of wax supercassettes, 75x52x19 mm....
... is of rotary retracting, self-lubricating design and has ... Its robust construction makes it accurate and incredibly ... that all lateral motion is controlled and allows ... in other, lesser designs which can result in ...
Medicine Products: